Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.49 |
| ▸ | PI4KA | P42356 | 1/20 | 0.49 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.49 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.49 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.49 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.42 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.42 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.42 |
| ▸ | P2RY12 | Q9H244 | 2/20 | 0.41 |
| ▸ | AMD1 | P17707 | 2/20 | 0.40 |
| ▸ | NNMT | P40261 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1798087 | 0.88 | RXFP1 (0.61) | RXFP1PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL1798372 | 0.85 | PI4KA (0.65) | RXFP1PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL11890143 | 0.85 | PI4KA (0.65) | RXFP1PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL1797308 | 0.84 | NNMT (0.51) | NNMT | |
| SCHEMBL1801715 | 0.83 | RXFP1 (0.50) | RXFP1PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL18314858 | 0.83 | PI4KA (0.70) | RXFP1PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL1799357 | 0.83 | RXFP1 (0.57) | RXFP1PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL1800390 | 0.83 | RXFP1 (0.57) | RXFP1PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL1801717 | 0.82 | RXFP1 (0.49) | RXFP1PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL1794414 | 0.82 | RXFP1 (0.56) | RXFP1PI4KAPI4K2BPI4K2API4KB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180086785-A1 | SUBSTITUTED PYRROLO[2,3-D]PYRIMIDINES | MILLENNIUM PHARMACEUTICALS, INC. | 2018-03-29 | — | — | US | disclosed |
| US-20170073367-A9 | SUBSTITUTED PYRROLO[2,3-D]PYRIMIDINES | MILLENIUM PHARMACEUTICALS, INC. | 2017-03-16 | — | — | US | disclosed |
| US-20160194348-A1 | SUBSTITUTED PYRROLO[2,3-D]PYRIMIDINES | MILLENNIUM PHARM INC (US) | 2016-07-07 | — | — | US | disclosed |
| EP-1848718-B1 | INHIBITORS OF E1 ACTIVATING ENZYMES | MILLENNIUM PHARM INC (US) | 2012-08-01 | — | — | EP | disclosed |
| US-20110136834-A1 | INHIBITORS OF E1 ACTIVATING ENZYMES | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180086785-A1 | SUBSTITUTED PYRROLO[2,3-D]PYRIMIDINES | TYMP, TYMS, PPA1 | RXFP1 3880/4885PI4KA 1455/4885PI4K2B 2027/4885 |
| US-20170073367-A9 | SUBSTITUTED PYRROLO[2,3-D]PYRIMIDINES | TYMP, TYMS, PPA1 | RXFP1 3880/4885PI4KA 1455/4885PI4K2B 2027/4885 |
| US-20110136834-A1 | INHIBITORS OF E1 ACTIVATING ENZYMES | ECE1, RNASE1, RCE1 | RXFP1 3167/4885PI4KA 1991/4885PI4K2B 2891/4885 |
| US-20160194348-A1 | SUBSTITUTED PYRROLO[2,3-D]PYRIMIDINES | TYMP, TYMS, PPA1 | RXFP1 3880/4885PI4KA 1455/4885PI4K2B 2027/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.